LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
LifeMine Therapeutics has raised $175.0M in total funding. The most recent round was Series C. The last funding was announced in March 2022.
LifeMine Therapeutics's investors include ARCH Venture Partners, Foresite Capital, Merck, Fidelity, Google Ventures.
LifeMine Therapeutics is headquartered in Cambridge, United States.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
LifeMine Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LifeMine Therapeutics — Funding & Investors." VCBacked, March 23, 2022, https://www.vcbacked.co/company/lifemine-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). LifeMine Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/lifemine-therapeutics
{{cite web |title=LifeMine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lifemine-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated